Thromb Haemost 1987; 58(04): 0998-1004
DOI: 10.1055/s-0038-1646044
Original Article
Schattauer GmbH Stuttgart

Immunoradiometric Assay for the Calcium-Stabilized Conformation of Human Protein S

Authors

  • S R Poort

    The Hemostasis and Thrombosis Research Unit, Department of Hematology, Leiden University Hospital, Leiden, The Netherlands
  • P P Deutz-Terlouw

    The Hemostasis and Thrombosis Research Unit, Department of Hematology, Leiden University Hospital, Leiden, The Netherlands
  • A van Wijngaarden

    The Hemostasis and Thrombosis Research Unit, Department of Hematology, Leiden University Hospital, Leiden, The Netherlands
  • R M Bertina

    The Hemostasis and Thrombosis Research Unit, Department of Hematology, Leiden University Hospital, Leiden, The Netherlands
Further Information

Publication History

Received 20 March 1987

Accepted after revision 29 July 1987

Publication Date:
29 June 2018 (online)

Preview

Summary

Rabbit polyclonal anti-protein S serum was fractionated with immobilized human protein S to establish solid-phase immunoradiometric assays recognizing Ca(II)-dependent and NonCa(II)-dependent epitopes of human protein S. The two assays were specific for PS:Ca(II)Ag and PS:NonCa(II)Ag and highly sensitive with a lower limit of detection of about 2.5 ng/ml.

PS:Ca(II)Ag and PS:NonCa(II)Ag levels were measured in immunopurified protein S, thrombin-modified protein S and chy-motrypsin-cleaved protein S. Only in chymotrypsin-cleaved protein S an important discrepancy between the two antigen levels was observed.

Ranges for the concentration of PS:Ca(II)Ag and PS:NonCa(II)Ag and their ratio were established in plasma of healthy individuals (0.92 ± 0.13 U/ml, 0.98 ± 0.21 U/ml, 0.96 ± 0.17, respectively). In a group of patients using oral anticoagulant therapy the ratio PS:Ca(II) Ag/PS : NonCa(II)Ag decreased at increasing intensity of anticoagulation suggesting the presence of sub- and noncarboxylated protein S molecules.

In plasma of patients with a hereditary type I protein S deficiency PS:Ca(II)Ag and PS:NonCa(II) Ag were reduced to the same extent: mean ratio 1.02 ± 0.12 in the group not on oral anticoagulant treatment and 0.94 ± 0.10 in the group on oral anticoagulant therapy. Analysis of patients with a history of unexplained thrombo-embolic disease did not reveal individual patients with a PS:Ca(II)Ag/PS:NonCa(II)Ag ratio below the lower limit of the normal range (mean ratio 1.05 ± 0.17), suggesting that the frequency of genetic protein S variants with defects in the Ca(II)-stabilized conformation is very low.